The United States has initiated an investigation into Germany’s pharmaceutical pricing policies, citing concerns over unfair underpayment for innovative medicines. The probe, launched under Section 301 trade authorities, will assess whether German practices negatively impact US commerce. Washington alleges that Germany’s pricing methods create a trade imbalance and potentially warrant retaliatory tariffs. This action escalates trade tensions between the two nations, focusing on the pharmaceutical sector. The investigation will examine the impact of German policies on US pharmaceutical companies and their ability to recoup research and development costs. The outcome could lead to the imposition of new tariffs on German goods if the US determines unfair trade practices are occurring. This move signals a continued US focus on trade enforcement and protecting its pharmaceutical industry.